Entries in Viibryd (2)


FDA Approves Antidepressant with Fewer Sexual Side Effects

Photo Courtesy - PRNewsFoto/U.S. Food and Drug Administration (FDA)(WASHINGTON) -- While antidepressants help many people enjoy life once again, that enjoyment can come at the cost of one's sex life.

Sexual side effects are a common complaint lodged against a number of antidepressant drugs, especially those in the group called selective serotonin reuptake inhibitors, or SSRIs. The Food and Drug Administration recently approved another antidepressant, Viibryd, which holds the promise of having a less-adverse effect on the libido.

"In the two clinical studies done so far, there was no sign of sexual side effects," said Dr. Norman Sussman, a professor of psychiatry at New York University Langone Medical Center.

Although Viibryd is technically an SSRI, it is a dual-action drug -- it increases the body's level of serotonin -- a neurotransmitter that contributes to feelings of well-being and also activates a serotonin receptor.

Experts believe it's the action on this serotonin receptor that helps reduce sexual side effects, although they're not sure exactly how.

Decreased sex drive, difficulty reaching orgasm and erectile dysfunction are among the complications associated with several other antidepressants on the market, such as Effexor, Celexa and Prozac, all SSRIs, but are much less common with another type of antidepressants called monoamine oxidase inhibitors.

Copyright 2011 ABC News Radio


FDA Approves New Drug for Major Depression

Photo Courtesy - Getty Images(SILVER SPRING, Md.) -- The U.S. Food and Drug Administration approved a new drug called Viibryd Friday to treat major depressive disorder (also called major depression) in adults. 

Viibryd, which will be available in 10, 20 and 40 milligram tablets, will treat symptoms including depressed mood, loss of interest in usual activities, radical change in weight or appetite and insomnia or restlessness.

"Major depressive disorder is disabling and prevents a person from functioning normally," said Dr. Thomas Laughren, director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research.  Dr. Laughren stressed the importance of providing a variety of treatment options for depression patience because medications affect everyone differently.

The FDA warns that while the drug showed no increased risks in adults older than 24, children and young adults may experience increased risk of suicidal thinking. 

Copyright 2011 ABC News Radio

ABC News Radio